Press about RVC

World's First Gene Therapy Drug for Cancer Treatment to Be Created in Russia

An interdepartmental working group on the implementation of the National Technological Initiative (NTI) approved a grant of 125 million rubles for the development of the world's first gene therapy drug for cancer treatment. This was announced on Wednesday by the press service of Russian Venture Company (RVC).

“The Interdepartmental Working Group on the implementation of NTI approved the support of the project on the development of the gene therapy anti-tumour drug AntioncoRAN-M within the framework of the NTI Helsnet roadmap. During the project, it is planned to develop and market the world's first non-viral gene therapy drug for cancer treatment, which will increase the efficiency and safety of treating cancer patients,” the report said.

It is noted that the NTI project support fund will allocate a grant of 125 million rubles to AntioncoRAN-M. In case of successful completion of the first stage, investments in the authorized capital are planned. At the expense of NTI, as noted in the press service, it is intended to complete preclinical studies of the drug and conduct clinical studies of the I-III phase (there are four such phases). The launch of the medicine onto the market is planned after 2025.

AntioncoRAN-M, the developer of which is the biotechnological company Genetic Surgery LLC, implements a cancer gene therapy approach that involves delivering the so-called killer genes to the tumour, the product of which destroys cancer cells. As well as the delivery of the immunostimulant gene, the protein of which activates the antitumour immune response, as a result of which the process of the appearance of metastases is suppressed. The process takes place inside the tumour, which reduces its toxicity to healthy tissues and organs.

The drug can be used to treat cancer of the head and neck, rectum, cervix, sarcoma, and other types of solid tumours. It differs from other gene therapeutic antitumour drugs available on the market and in clinical trials by the simplicity and low cost of production, as well as low immunogenicity and toxicity. According to the developers, they expect to receive permission for clinical studies from the Ministry of Health of the Russian Federation in 2021.

NTI is a long-term program to create new markets and provide conditions for Russia's technological leadership by 2035. Within the framework of the NTI, eight road maps were approved for the Aeronet, Neuronet, Helsnet, Energy market, and so on. The Helsnet market is aimed at developing personalized medical services and medicines that provide an increase in life expectancy, as well as obtaining new effective means of preventing and treating various diseases. According to forecasts, by 2035, the global Helsnet market within the worldwide healthcare market will reach more than $9 trillion.

Search by name:

Search by date:

Select date in calendar
Select date in calendar